TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced financial results for the first quarter ended March 31, 2017, as well as a corporate update.
“We continue to execute on our strategy to develop VB-111, a targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors,” said Professor Dror Harats, Chief Executive Officer of VBL Therapeutics. “Our GLOBE pivotal trial in rGBM has completed enrollment and the DSMB committee reviewed the GLOBE safety data collected through a cutoff date in March 2017 and unanimously recommended that the study continue as planned. Based on the current event rate in this trial, we now expect the interim analysis to occur in the third quarter of 2017, with top line data from the full dataset becoming available in early 2018. Our planned Phase 3 clinical trial of VB-111 in ovarian cancer is expected to begin in the second half of 2017.”
